GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » Sopharma AD-Sofia (WAR:SPH) » Definitions » Cyclically Adjusted Price-to-FCF

Sopharma AD-Sofia (WAR:SPH) Cyclically Adjusted Price-to-FCF : (As of Jun. 28, 2025)


View and export this data going back to 2011. Start your Free Trial

What is Sopharma AD-Sofia Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Sopharma AD-Sofia Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Sopharma AD-Sofia's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sopharma AD-Sofia Cyclically Adjusted Price-to-FCF Chart

Sopharma AD-Sofia Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Sopharma AD-Sofia Quarterly Data
Jun19 Sep19 Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Sopharma AD-Sofia's Cyclically Adjusted Price-to-FCF

For the Medical Distribution subindustry, Sopharma AD-Sofia's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sopharma AD-Sofia's Cyclically Adjusted Price-to-FCF Distribution in the Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Sopharma AD-Sofia's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Sopharma AD-Sofia's Cyclically Adjusted Price-to-FCF falls into.


;
;

Sopharma AD-Sofia Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Sopharma AD-Sofia's Cyclically Adjusted FCF per Share for the quarter that ended in Jun. 2024 is calculated as:

For example, Sopharma AD-Sofia's adjusted Free Cash Flow per Share data for the three months ended in Jun. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Jun. 2024 (Change)*Current CPI (Jun. 2024)
=1.594/132.5538*132.5538
=1.594

Current CPI (Jun. 2024) = 132.5538.

Sopharma AD-Sofia Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 -0.125 100.560 -0.165
201409 0.074 100.428 0.098
201412 0.282 99.070 0.377
201503 0.024 99.621 0.032
201506 0.091 100.684 0.120
201509 0.259 100.392 0.342
201512 0.371 99.792 0.493
201603 -0.283 100.470 -0.373
201606 -0.331 101.688 -0.431
201609 -0.642 101.861 -0.835
201612 -0.207 101.863 -0.269
201703 -0.253 102.862 -0.326
201706 -0.694 103.349 -0.890
201709 -0.024 104.136 -0.031
201712 -0.399 104.011 -0.508
201803 -0.528 105.290 -0.665
201806 -0.970 106.317 -1.209
201809 -0.532 106.507 -0.662
201812 -0.584 105.998 -0.730
201903 -0.782 107.251 -0.966
201906 -0.832 108.070 -1.020
201909 -0.853 108.329 -1.044
201912 -0.444 108.420 -0.543
202006 0.000 108.767 0.000
202009 -0.724 109.815 -0.874
202012 -0.695 109.897 -0.838
202103 -0.415 111.754 -0.492
202106 -0.615 114.631 -0.711
202109 -0.483 115.734 -0.553
202112 -0.238 117.630 -0.268
202203 0.199 121.301 0.217
202206 0.121 125.017 0.128
202209 0.067 125.227 0.071
202212 1.040 125.222 1.101
202303 0.099 127.348 0.103
202306 -0.510 128.729 -0.525
202309 -1.110 129.860 -1.133
202312 1.253 129.419 1.283
202403 -2.778 131.776 -2.794
202406 1.594 132.554 1.594

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Sopharma AD-Sofia  (WAR:SPH) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Sopharma AD-Sofia Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Sopharma AD-Sofia's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Sopharma AD-Sofia Business Description

Traded in Other Exchanges
Address
5 Lachezar Stanchev Street, Sopharma Business Towers, Building A, Floor 11, Sofia, BGR, 1756
Sopharma AD-Sofia is a company engaged in the production of pharmaceutical products. Its principal activities include the production and trade of medicinal substances and finished drug forms; and research and development as well as engineering and implementation activities in the field of medicinal products. It is also focused on the distribution of pharmaceuticals like medical supplies, sanitary materials, vitamins, food supplements, and cosmetics. The company's segments are the Production of pharmaceutical products; Distribution of pharmaceutical products; and Others. It generates the majority of its revenue from the Distribution of pharmaceutical products.